UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of August 2021

 

001-36203

(Commission File Number)

 

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

 

10 Bareket Street

Kiryat Matalon, P.O. Box 7537

Petach-Tikva 4951778, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F        Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

 

This Report on Form 6-K (including Exhibits 99.1 and 99.2 and the text under the heading “Financial Results”, the accompanying interim condensed consolidated financial statements and “Forward-Looking Statements” in the press release in Exhibit 99.3) is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-227753) and Form F-3 (File Nos. 333-195124, 333-236064, and 333-249063), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

 

 

 

On August 26, 2021, Can-Fite BioPharma Ltd. (the “Company”) issued a press release announcing financial results for the six months ended June 30, 2021 and updates on its drug development programs. In addition, on the same day, the Company issued unaudited interim condensed consolidated financial statements as of June 30, 2021. Attached hereto and incorporated by reference herein are the following exhibits:

 

99.1 Operating and Financial Review and Prospects as of June 30, 2021
   
99.2 Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2021
   
99.3 Press Release dated August 26, 2021

 

1

 

Exhibit Index

 

Exhibit No.   Description
     
99.1   Operating and Financial Review and Prospects as of June 30, 2021
     
99.2   Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2021
     
99.3   Press Release dated August 26, 2021

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Can-Fite BioPharma Ltd.
     
Date: August 26, 2021 By: /s/ Pnina Fishman
    Pnina Fishman
    Chief Executive Officer

 

3

 

false --12-31 Q2 2021 2021-06-30 0001536196
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Can Fite BioPharma Charts.
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Can Fite BioPharma Charts.